Curated News
By: NewsRamp Editorial Staff
March 09, 2026

HeartBeam Showcases Revolutionary 3D ECG Tech at Major 2026 Medical Conferences

Discuss on LinkedIn Discuss on Telegram
Original Source

TLDR

  • HeartBeam's investor conference participation offers early insight into its FDA-cleared 3D ECG technology, potentially providing investment advantages in portable cardiac monitoring.
  • HeartBeam's cable-free device collects ECG signals from three directions, synthesizes them into 12-lead ECGs, and received FDA clearance for arrhythmia assessment in December 2025.
  • HeartBeam's portable ECG technology enables cardiac monitoring outside medical facilities, improving early detection and potentially saving lives through accessible heart health management.
  • HeartBeam showcases a working prototype of its 12-lead ECG extended wear patch at cardiology conferences, demonstrating cable-free cardiac monitoring technology.

Impact - Why it Matters

This development matters because HeartBeam's technology addresses critical gaps in cardiac care by enabling comprehensive ECG monitoring outside traditional medical facilities. Cardiovascular disease remains a leading cause of death globally, and early detection of arrhythmias and other cardiac conditions significantly improves patient outcomes. Current ECG technology often requires clinical visits and cumbersome equipment, creating barriers to continuous monitoring. HeartBeam's portable 3D ECG system could democratize access to sophisticated cardiac diagnostics, allowing for earlier intervention, reduced hospitalizations, and better management of chronic conditions. For patients, this means potentially life-saving monitoring can occur during daily activities, while healthcare systems benefit from reduced costs associated with emergency care and hospital readmissions. The technology's FDA clearance and patent portfolio suggest strong validation of its medical and commercial potential.

Summary

HeartBeam (NASDAQ: BEAT), a pioneering medical technology company focused on transforming cardiac care, has announced an active March 2026 conference schedule where its leadership team will showcase groundbreaking innovations and engage with key stakeholders. CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation, while also meeting with institutional and retail investors. The executives will then attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel discussion on technologies advancing healthy aging. Most significantly, Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology's annual scientific conference on March 28-30, where the company will demonstrate its FDA-cleared HeartBeam System and a working prototype of its revolutionary 12-lead ECG extended wear patch to physicians and potential industry partners.

HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, representing a significant leap forward in portable cardiac monitoring. This platform technology is designed for use wherever patients are located, delivering actionable heart intelligence that enables physicians to identify cardiac health trends and acute conditions outside traditional medical facilities. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for its 12-lead ECG synthesis software in December 2025, with the company holding over 20 issued patents related to this transformative technology. The press release was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on biotechnology and life sciences sectors, providing enhanced press release distribution and corporate communications solutions.

HeartBeam's technology represents a paradigm shift in cardiac care by enabling comprehensive ECG monitoring outside clinical settings, potentially revolutionizing how heart conditions are detected and managed. The company's participation in these high-profile conferences demonstrates its commitment to advancing cardiac health management through innovative technology that could significantly improve patient outcomes and reduce healthcare costs. By providing physicians with detailed cardiac insights from portable devices, HeartBeam aims to redefine the future of cardiac care, making sophisticated monitoring accessible to patients wherever they are. The full press release can be viewed at https://ibn.fm/tnwvK, and additional updates about HeartBeam are available through the company's newsroom at https://ibn.fm/BEAT, distributed via the BioMedWire platform that serves the biotechnology and biomedical sciences sectors with comprehensive communications solutions.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Showcases Revolutionary 3D ECG Tech at Major 2026 Medical Conferences

blockchain registration record for this content.